

```

-----  

? s (pressure? (n) sore?) or decubit? or (ischial (n) tuberos?) or bedsore? or (bed  

(n) sore?)  

    3807992 PRESSURE?  

    76859 SORE?  

    8545 PRESSURE? (N) SORE?  

    23185 DECUBIT?  

    3593 ISCHIAL  

    77033 TUBEROS?  

    1442 ISCHIAL (N) TUBEROS?  

    1852 BEDSORE?  

    480426 BED  

    76859 SORE?  

    661 BED (N) SORE?  

S1 31523 (PRESSURE? (N) SORE?) OR DECUBIT? OR (ISCHIAL (N)  

TUBEROS?) OR BEDSORE? OR (BED (N) SORE?)  


```

? s s1/2003:2007

Processing

Processed 10 of 25 files ...

>>>One or more prefixes are unsupported

>>> or undefined in one or more files.

>>>Year ranges not supported in one or more files

Completed processing all files

```

    31412 S1  

    25144667 PY=2003 : PY=2007  

    S2    7507 S1/2003:2007

```

? s s1 not s2

```

    31523 S1  

    7507 S2  

    S3    24016 S1 NOT S2

```

? e botulinum toxin

| Ref | Items | RT | Index-term                                   |
|-----|-------|----|--|
| E1  | 1     |    | BOTULINUM TOXI                               |
| E2  | 2     |    | BOTULINUM TOXICITY                           |
| E3  | 11195 | 20 | *BOTULINUM TOXIN                             |
| E4  | 1     |    | BOTULINUM TOXIN (BOTOX)                      |
| E5  | 4     |    | BOTULINUM TOXIN (BOTX)                       |
| E6  | 1     |    | BOTULINUM TOXIN (THERAPEUTIC USE)            |
| E7  | 509   |    | BOTULINUM TOXIN --ADVERSE DRUG REACTION --AE |
| E8  | 340   |    | BOTULINUM TOXIN --CLINICAL TRIAL --CT        |
| E9  | 204   |    | BOTULINUM TOXIN --DRUG ADMINISTRATION --AD   |
| E10 | 22    |    | BOTULINUM TOXIN --DRUG ANALYSIS --AN         |
| E11 | 48    |    | BOTULINUM TOXIN --DRUG COMBINATION --CB      |
| E12 | 101   |    | BOTULINUM TOXIN --DRUG COMPARISON --CM       |

Enter P or PAGE for more

? s e3

```

    S4    11195 'BOTULINUM TOXIN'

```

? e e3

| Ref | Items | Type | RT  | Index-term                     |
|-----|-------|------|-----|--------------------------------|
| R1  | 6698  |      | 20  | *BOTULINUM TOXIN               |
| R2  | 47805 |      |     | DC=D5.80.90.80                 |
| R3  | 5093  | B    | 130 | BACTERIAL TOXIN                |
| R4  | 0     | S    | 2   | BOTULINAL TOXIN TEST           |
| R5  | 0     | S    | 2   | BOTULINUM TOXIN                |
| R6  | 0     | S    | 2   | BOTULINUM NEUROTOXIN           |
| R7  | 0     | S    | 2   | BOTULINUM TOXINS               |
| R8  | 0     | S    | 2   | BOTULINUS TOXIN                |
| R9  | 0     | S    | 2   | BOTULISM TOXIN                 |
| R10 | 0     | S    | 2   | CLOSTRIDIUM BOTULINUM EXOTOXIN |
| R11 | 0     | S    | 2   | CLOSTRIDIUM BOTULINUM TOXIN    |

? p

SYSTEM:OS - DIALOG OneSearch  
File 155: MEDLINE(R) 1950-2007/Jun 11  
(c) format only 2007 Dialog  
\*File 155: Medline has been reloaded. Please see HELP NEWS 154  
for information on 2007 changes.  
File 5: BIOSIS Previews(R) 1926-2007/Jun W2  
(c) 2007 The Thomson Corporation  
\*File 5: BIOSIS has been enhanced with archival data. Please see  
HELP NEWS 5 for information.  
File 34: SciSearch(R) Cited Ref Sci 1990-2007/Jun W2  
(c) 2007 The Thomson Corp  
File 35: Dissertation Abs Online 1861-2007/May  
(c) 2007 ProQuest Info&Learning  
File 45: EMCare 2007/Jun W1  
(c) 2007 Elsevier B.V.  
File 65: Inside Conferences 1993-2007/Jun 13  
(c) 2007 BLDSC all rts. reserv.  
File 71: ELSEVIER BIOBASE 1994-2007/Jun W1  
(c) 2007 Elsevier B.V.  
File 73: EMBASE 1974-2007/Jun 06  
(c) 2007 Elsevier B.V.  
File 91: MANTIS(TM) 1880-2007/Apr  
2001 (c) Action Potential  
File 98: General Sci Abs 1984-2007/Jun  
(c) 2007 The HW Wilson Co.  
File 135: NewsRx Weekly Reports 1995-2007/Jun W1  
(c) 2007 NewsRx  
File 144: Pascal 1973-2007/Jun W1  
(c) 2007 INIST/CNRS  
File 149: TGG Health&Wellness DB(SM) 1976-2007/Jun W1  
(c) 2007 The Gale Group  
File 156: ToxFile 1965-2007/Jun W2  
(c) format only 2007 Dialog  
File 159: Cancerlit 1975-2002/Oct  
(c) format only 2002 Dialog  
\*File 159: Cancerlit is no longer updating.  
Please see HELP NEWS159.  
File 162: Global Health 1983-2007/Apr  
(c) 2007 CAB International  
File 164: Allied & Complementary Medicine 1984-2007/Jun  
(c) 2007 BLHCIS  
File 172: EMBASE Alert 2007/Jun 06  
(c) 2007 Elsevier B.V.  
File 266: FEDRIP 2007/May  
Comp & dist by NTIS, Intl Copyright All Rights Res  
File 369: New Scientist 1994-2007/Jan W1  
(c) 2007 Reed Business Information Ltd.  
File 370: Science 1996-1999/Jul W3  
(c) 1999 AAAS  
\*File 370: This file is closed (no updates). Use File 47 for more current  
information.  
File 399: CA SEARCH(R) 1967-2007/UD=14625  
(c) 2007 American Chemical Society  
\*File 399: Use is subject to the terms of your user/customer agreement.  
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.  
File 434: SciSearch(R) Cited Ref Sci 1974-1989/Dec  
(c) 2006 The Thomson Corp  
File 444: New England Journal of Med. 1985-2007/May W4  
(c) 2007 Mass. Med. Soc.  
File 467: ExtraMED(tm) 2000/Dec  
(c) 2001 Informania Ltd.

Set Items Description

updated  
ref search  
6/07  
JFB

>>>Related terms display completed...

? e r1

| Ref | Items | Type | RT  | Index-term                     |
|-----|-------|------|-----|--------------------------------|
| R1  | 6698  |      | 20  | *BOTULINUM TOXIN               |
| R2  | 47805 |      |     | DC=D5.80.90.80                 |
| R3  | 5093  | B    | 130 | BACTERIAL TOXIN                |
| R4  | 0     | S    | 2   | BOTULINAL TOXIN TEST           |
| R5  | 0     | S    | 2   | BOTULINUM TOXIN                |
| R6  | 0     | S    | 2   | BOTULINUM NEUROTOXIN           |
| R7  | 0     | S    | 2   | BOTULINUM TOXINS               |
| R8  | 0     | S    | 2   | BOTULINUS TOXIN                |
| R9  | 0     | S    | 2   | BOTULISM TOXIN                 |
| R10 | 0     | S    | 2   | CLOSTRIDIUM BOTULINUM EXOTOXIN |
| R11 | 0     | S    | 2   | CLOSTRIDIUM BOTULINUM TOXIN    |

? p

>>>Related terms display completed...

? s r1:r2

>>>One or more prefixes are unsupported

>>> or undefined in one or more files.

S5 49513 R1:R2

? e botulinum toxins

| Ref | Items | RT | Index-term                                     |
|-----|-------|----|--|
| E1  | 1     |    | BOTULINUM TOXINE A                             |
| E2  | 1     |    | BOTULINUM TOXINE TYPE A                        |
| E3  | 10565 | 39 | *BOTULINUM TOXINS                              |
| E4  | 1773  |    | BOTULINUM TOXINS --ADMINISTRATION AND DOSAGE - |
| E5  | 740   |    | BOTULINUM TOXINS --ADVERSE EFFECTS --AE        |
| E6  | 595   |    | BOTULINUM TOXINS --ANALYSIS --AN               |
| E7  | 128   |    | BOTULINUM TOXINS --ANTAGONISTS AND INHIBITORS  |
| E8  | 428   |    | BOTULINUM TOXINS --BIOSYNTHESIS --BI           |
| E9  | 155   |    | BOTULINUM TOXINS --BLOOD --BL                  |
| E10 | 4     |    | BOTULINUM TOXINS --CHEMICAL SYNTHESIS --CS     |
| E11 | 476   |    | BOTULINUM TOXINS --CHEMISTRY --CH              |
| E12 | 125   |    | BOTULINUM TOXINS --CLASSIFICATION --CL         |

Enter P or PAGE for more

? s e3

S6 10565 'BOTULINUM TOXINS'

? e e3

| Ref | Items | Type | RT  | Index-term                   |
|-----|-------|------|-----|------------------------------|
| R1  | 9982  |      | 39  | *BOTULINUM TOXINS            |
| R2  | 6698  | U    | 20  | BOTULINUM TOXIN              |
| R3  | 5097  | X    |     | DC=D12.776.97.156.           |
| R4  | 5097  | X    |     | DC=D23.946.123.179.          |
| R5  | 184   | X    | 2   | BOTULIN                      |
| R6  | 0     | X    | 2   | CLOSTRIDIUM BOTULINUM TOXINS |
| R7  | 2670  | R    | 20  | BOTULISM                     |
| R8  | 1102  | R    | 222 | CHOLINERGIC AGENTS           |
| R9  | 2090  | R    | 22  | CLOSTRIDIUM BOTULINUM        |
| R10 | 768   | B    | 56  | ANTI-DYSKINESIA AGENTS       |
| R11 | 89425 | B    | 90  | BACTERIAL PROTEINS           |
| R12 | 16696 | B    | 42  | BACTERIAL TOXINS             |

Enter P or PAGE for more

? p

| Ref | Items | Type | RT  | Index-term              |
|-----|-------|------|-----|-------------------------|
| R13 | 318   | B    | 468 | NOXAE                   |
| R14 | 4297  | B    | 86  | POISONS                 |
| R15 | 2977  | N    | 12  | BOTULINUM TOXIN TYPE A  |
| R16 | 144   | X    |     | DC=D24.185.926.123.179. |

|     |      |   |                                |
|-----|------|---|--------------------------------|
| R17 | 144  | X | DC=D24.185.926.640.75.         |
| R18 | 6    | X | 1 BOTULIN                      |
| R19 | 0    | X | 1 CLOSTRIDIUM BOTULINUM TOXINS |
| R20 | 30   | R | 10 BOTULISM                    |
| R21 | 46   | R | 108 CHOLINERGIC AGENTS         |
| R22 | 24   | R | 5 CLOSTRIDIUM BOTULINUM        |
| R23 | 20   | B | 29 ANTI-DYSKINESIA AGENTS      |
| R24 | 1247 | B | 16 BACTERIAL TOXINS            |

Enter P or PAGE for more

? p

| Ref | Items | Type | RT | Index-term             |
|-----|-------|------|----|------------------------|
| R25 | 785   | B    | 15 | NEUROTOXINS            |
| R26 | 49    | N    | 4  | BOTULINUM TOXIN TYPE A |

? p

>>>Related terms display completed...  
? s r1 or r2 or r3 or r4 or r5 or r7:r9 or r15:r23 or r26

>>>One or more prefixes are unsupported

>>> or undefined in one or more files.

|          |  |
|----------|--|
| 9982     | BOTULINUM TOXINS   |
| 6698     | BOTULINUM TOXIN  |
| 9820     | DC=D12.776.97.156.   |
| 9820     | DC=D23.946.123.179.  |
| 321      | BOTULIN  |
| 9182     | BOTULISM:CLOSTRIDIUM BOTULINUM   |
| 5546     | BOTULINUM TOXIN TYPE A:ANTI-DYSKINESIA AGENTS  |
| 49       | BOTULINUM TOXIN TYPE A   |
| S7 28332 | 'BOTULINUM TOXINS' OR 'BOTULINUM TOXIN' OR<br>DC='D12.776.97.156.' OR DC='D23.946.123.179.' OR<br>'BOTULIN' OR R7:R9 OR R15:R23 OR R26 |

? ds

| Set                      | Items  | Description  |
|--------------------------|--|--|
| S1                       | 31523  | (PRESSURE? (N) SORE?) OR DECUBIT? OR (ISCHIAL (N) TUBEROS?)<br>OR BEDSORE? OR (BED (N) SORE?)  |
| S2                       | 7507   | S1/2003:2007   |
| S3                       | 24016  | S1 NOT S2  |
| S4                       | 11195  | 'BOTULINUM TOXIN'  |
| S5                       | 49513  | R1:R2  |
| S6                       | 10565  | 'BOTULINUM TOXINS'   |
| S7                       | 28332  | 'BOTULINUM TOXINS' OR 'BOTULINUM TOXIN' OR DC='D12.776.97.-<br>156.' OR DC='D23.946.123.179.' OR 'BOTULIN' OR R7:R9 OR R15:R-<br>23 OR R26 |
| ? s s4 or s5 or s6 or s7 | 11195 49513 10565 28332                              | S4 S5 S6 S7  |
| ? s s3 and s8            | 24016 76181  | S3 S8  |
| S9                       | 15   | S3 AND S8  |
| ? rd                     | S10  | 12 RD (unique items)   |
| ? t s10/free/all         | >>>"FREE" is not a valid format name in file(s): 399 |  |

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#) [Generate Collection](#) [Print](#)

L12: Entry 54 of 382

File: PGPB

Mar 30, 2006

DOCUMENT-IDENTIFIER: US 20060064800 A1

TITLE: Decubitus ulcer prevention and treatment

**Brief Summary Text:**

[0003] Specifically, although arterial inflow can continue and withstand pressure upwards of 170-mm Hg or greater, venous return or blood flow from a region is restricted or obstructed with pressures as low as 32-mm Hg on the skin and underlying tissue. The restriction or obstruction of the venous return of blood from the skin and underlying tissue may lead to the buildup of toxins and waste products that may lead to the formation of decubitus ulcers. Initially, pressure on the skin and tissue may lead to pink coloration and/or mild inflammation, which may disappear within a few hours of relieving pressure on the area. If pressure is not relieved, superficial lesions may form on the skin, then turning into ulcers which continue growing deeper until extending through the bone to internal organs, eventually becoming fatal to the patient.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

DERWENT-ACC-NO: 2005-664138

DERWENT-WEEK: 200720

COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: Treating or preventing development of pressure sores comprises local administration of a Botulinum toxin

INVENTOR: FIRST, E R; FIRST, E

PRIORITY-DATA: 2004US-0814764 (March 31, 2004)

PATENT-FAMILY:

| PUB-NO  | PUB-DATE          | LANGUAGE | PAGES | MAIN-IPC   |
|---|-------------------|----------|-------|------------|
| <input type="checkbox"/> <a href="#"><u>AU 2005231360 A1</u></a>  | October 20, 2005  |          | 000   | A61K038/48 |
| <input type="checkbox"/> <a href="#"><u>US 20050220821 A1</u></a> | October 6, 2005   |          | 016   | A61K039/08 |
| <input type="checkbox"/> <a href="#"><u>WO 2005097178 A1</u></a>  | October 20, 2005  | E        | 000   | A61K038/48 |
| <input type="checkbox"/> <a href="#"><u>EP 1729796 A1</u></a>     | December 13, 2006 | E        | 000   | A61K038/43 |

INT-CL (IPC): A61K 38/43; A61K 38/48; A61K 39/08; A61P 17/00; A61P 17/02

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

Detailed Description Text (5):

Referring to the characteristic features of these conventional wound treatment agents, the boric acid/zinc oxide ointment and zinc oxide ointment, containing zinc oxide which show locally protective action, mild astringency and weak antisepsis, are applied topically for efficacy in all phases of eczema, abrasio and other general skin diseases, blister, pustule, erosion, and ulcer. Solcoseryl ointment contains a component derived by extraction from calves, has a tissue respiration stimulating action, and is claimed to be effective in the promotion of granulation in the cases of decubitus, varicose ulcer, trauma, scald, burn and general surgical wounds. AD ointment, "Tokyo Tanabe", which contains as the effective ingredient vitamin A (10,000 IU/g-ointment), is intended to be directed toward wounds, abrasion, burn, scald, frostbite, skin ulcer and keratodermia, and is reputed for its efficacy as an agent for granulation and epidermization. Incidentally, vitamin A has been well known to affect the growth and differentiation of the skin tissue (Wolback, S. B. and Howe, P. R.; J. Exp. Med., 45, 753 (1925), Fell, H. B., Proc. Roy. Soc., B., 146, 242 (1957), and a report was made of the fact that vitamin A stimulates synthesis of DNA in the epidermis (Christophers, E. and Braun Falco, O.; Arch. Klin. Exper. Dermatol., 232, 427 (1968). In addition to the above, medicines having bactericidal effect (antibacterial action) such as an ointment containing chlorhexidine homologues are sometimes utilized.

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#) [Generate Collection](#) [Print](#)

L12: Entry 1 of 382

File: PGPB

Jun 7, 2007

DOCUMENT-IDENTIFIER: US 20070128228 A1

TITLE: BUTTOCK DEFORMITY TREATMENT

**Brief Summary Text:**

[0041] A botulinum toxin has also been proposed for or has been used to treat skin bone and tendon wounds (U.S. Pat. No. 6,447,787); intrathecal pain (see e.g. U.S. Pat. No. 6,113,915); various autonomic nerve disorders, including sweat gland disorders (see e.g. U.S. Pat. No. 5,766,605 and Goldman (2000), Aesthetic Plastic Surgery July-August 24(4):280-282); tension headache (U.S. Pat. No. 6,458,365); migraine headache pain (U.S. Pat. No. 5,714,468); post-operative pain and visceral pain (U.S. Pat. No. 6,464,986); hair growth and hair retention (U.S. Pat. No. 6,299,893); psoriasis and dermatitis (U.S. Pat. No. 5,670,484); injured muscles (U.S. Pat. No. 6,423,319); various cancers (see e.g. U.S. Pat. Nos. 6,139,845 and 6,063,768), smooth muscle disorders (U.S. Pat. No. 5,437,291); nerve entrapment syndromes (U.S. patent application 2003 0224019); acne (WO 03/011333); neurogenic inflammation (U.S. Pat. No. 6,063,768); otic disorders (see e.g. U.S. Pat. No. 6,265,379); pancreatic disorders (see e.g. U.S. Pat. Nos. 6,143,306 and 6,261,572); prostate disorders, including prostatic hyperplasia, prostate cancer and urinary incontinence (see e.g. U.S. Pat. Nos. 6,365,164 and 6,667,041 and Doggweiler R., et al Botulinum toxin type A causes diffuse and highly selective atrophy of rat prostate, Neurorol Urodyn 1998;17(4):363); fibromyalgia (U.S. Pat. No. 6,623,742), and piriformis muscle syndrome (see e.g. Childers et al. (2002), American Journal of Physical Medicine & Rehabilitation, 81:751-759).

**Brief Summary Text:**

[0045] It is known that a botulinum toxin can be used to: weaken the chewing or biting muscle of the mouth so that self inflicted wounds and resulting ulcers can heal (Payne M., et al, Botulinum toxin as a novel treatment for self mutilation in Lesch-Nyhan syndrome, Ann Neurol 2002 September;52(3 Supp 1):S157); permit healing of benign cystic lesions or tumors (Blugerman G., et al., Multiple eccrine hidrocystomas: A new therapeutic option with botulinum toxin, Dermatol Surg 2003 May;29(5):557-9); treat anal fissure (Jost W., Ten years' experience with botulinum toxin in anal fissure, Int J Colorectal Dis 2002 September;17(5):298-302, and; treat certain types of atopic dermatitis (Heckmann M., et al., Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study, J Am Acad Dermatol 2002 April;46(4):617-9).

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

PUB-NO: EP001128844A1

DOCUMENT-IDENTIFIER: EP 1128844 A1

TITLE: BOTULINUM TOXINS FOR ENHANCING WOUND HEALING

PUBN-DATE: September 5, 2001

INVENTOR-INFORMATION:

| NAME              | COUNTRY |
|-------------------|---------|
| GASSNER, HOLGER G | DE      |
| SHERRIS, DAVID A  | US      |

ASSIGNEE-INFORMATION:

| NAME                        | COUNTRY |
|-----------------------------|---------|
| MAYO FOUNDATION FOR MEDICAL | US      |

APPL-NO: EP99960130

APPL-DATE: October 15, 1999

PRIORITY-DATA: US10568898P (October 27, 1998)

INT-CL (IPC): A61K 38/16; A61K 31/445; A61K 31/167; A61K 31/137; A61P 17/02

EUR-CL (EPC): A61K031/505 ; A61K031/505 , A61K031/519 , A61K031/519 , A61K031/529 , A61K031/529 , A61K038/16 , A61K038/16

ABSTRACT:

[Previous Doc](#)    [Next Doc](#)    [Go to Doc#](#)

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#) [Generate Collection](#) [Print](#)

L12: Entry 22 of 382

File: PGPB

Dec 7, 2006

DOCUMENT-IDENTIFIER: US 20060272651 A1  
TITLE: DIVERSION BOARD/DIVERSION SHIELD

Description of Disclosure:

[0027] The diversion boards of the preferred embodiments can be used during numerous medical procedures and at numerous settings as readily understood by a skilled artisan. Examples of the numerous procedures include but are not limited to venipuncture--including IV placement, blood draws, injections (e.g., intramuscular, intravenous, subcutaneous) for sedation, vaccination, chemotherapy, botox treatment (e.g., for spasticity), etc.; biopsy; wound care; burn treatment; electromyography (EMG); or other medical treatment. While not being limited to a particular theory, exemplary settings for using the preferred diversion board include hospitals (e.g., treatment rooms, sedation rooms, emergency rooms), clinics, doctor's offices, laboratories, home, mobile units, or other locations where patient care is given. Moreover, the preferred diversion boards can be used in conjunction with other pain or stress reducing strategies, including but not limited to topical anesthetics, mild sedatives, acupuncture, massage, breathing exercises, audio, lighting and video.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

DERWENT-ACC-NO: 1996-371108

DERWENT-WEEK: 200381

COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: Controlled release collagen dosage form - is coherent, flat and conformable to wound size for direct application of active agent.

INVENTOR: EINIG, H; ROREGER, M

PATENT-ASSIGNEE: KNOLL AG (KNOL), LTS LOHmann THERAPIE-SYSTEME GMBH & CO (LOHM), LTS LOHmann THERAPIE-SYSTEME GMBH (LOHM)

PRIORITY-DATA: 1995DE-1003338 (February 2, 1995)

## PATENT-FAMILY:

| PUB-NO  | PUB-DATE           | LANGUAGE | PAGES | MAIN-IPC   |
|---|--------------------|----------|-------|------------|
| <input type="checkbox"/> <a href="#"><u>MX 211224 B</u></a>     | November 8, 2002   |          | 000   | A61K038/48 |
| <input type="checkbox"/> <a href="#"><u>WO 9623487 A1</u></a>   | August 8, 1996     | G        | 026   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>DE 19503338 A1</u></a>  | August 8, 1996     |          | 006   | A61L015/44 |
| <input type="checkbox"/> <a href="#"><u>ZA 9600795 A</u></a>    | September 25, 1996 |          | 022   | A61C000/00 |
| <input type="checkbox"/> <a href="#"><u>AU 9644873 A</u></a>    | August 21, 1996    |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>NO 9703525 A</u></a>    | July 31, 1997      |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>FI 9702949 A</u></a>    | August 28, 1997    |          | 000   | A61K000/00 |
| <input type="checkbox"/> <a href="#"><u>BR 9606997 A</u></a>    | October 28, 1997   |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>EP 809489 A1</u></a>    | December 3, 1997   | G        | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>CZ 9702219 A3</u></a>   | December 17, 1997  |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>SK 9701015 A3</u></a>   | April 8, 1998      |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>DE 19503338 C2</u></a>  | July 30, 1998      |          | 000   | A61L015/44 |
| <input type="checkbox"/> <a href="#"><u>KR 98701888 A</u></a>   | June 25, 1998      |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>AU 707364 B</u></a>     | July 8, 1999       |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>NZ 300202 A</u></a>     | October 28, 1999   |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>MX 9705806 A1</u></a>   | July 1, 1998       |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>US 6074664 A</u></a>    | June 13, 2000      |          | 000   | A61L015/38 |
| <input type="checkbox"/> <a href="#"><u>JP 2000515485 W</u></a> | November 21, 2000  |          | 019   | A61K038/46 |
| <input type="checkbox"/> <a href="#"><u>EP 809489 B1</u></a>    | May 16, 2001       | G        | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>DE 59606907 G</u></a>   | June 21, 2001      |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>ES 2159013 T3</u></a>   | September 16, 2001 |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>CN 1182364 A</u></a>    | May 20, 1998       |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>HU 200202088 A2</u></a> | September 30, 2002 |          | 000   | A61K009/70 |
| <input type="checkbox"/> <a href="#"><u>SK 282578 B6</u></a>    | October 8, 2002    |          | 000   | A61K009/70 |

CZ 290943 B6

November 13, 2002

000 A61K009/70

DESIGNATED-STATES: AU BG BR BY CA CN CZ FI HU JP KR MX NO NZ PL RO RU SG SI SK TR UA US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

CITED-DOCUMENTS:DE 3139089; DE 3606265 ; EP 194647 ; EP 260645 ; EP 49177

APPLICATION-DATA:

| PUB-NO        | APPL-DATE        | APPL-NO        | DESCRIPTOR     |
|---------------|------------------|----------------|----------------|
| MX 211224B    | January 25, 1996 | 1996WO-EP00294 |                |
| MX 211224B    | July 30, 1997    | 1997MX-0005806 |                |
| WO 9623487A1  | January 25, 1996 | 1996WO-EP00294 |                |
| DE 19503338A1 | February 2, 1995 | 1995DE-1003338 |                |
| ZA 9600795A   | February 1, 1996 | 1996ZA-0000795 |                |
| AU 9644873A   | January 25, 1996 | 1996AU-0044873 |                |
| AU 9644873A   |                  | WO 9623487     | Based on       |
| NO 9703525A   | January 25, 1996 | 1996WO-EP00294 |                |
| NO 9703525A   | July 31, 1997    | 1997NO-0003525 |                |
| FI 9702949A   | January 25, 1996 | 1996WO-EP00294 |                |
| FI 9702949A   | July 11, 1997    | 1997FI-0002949 |                |
| BR 9606997A   | January 25, 1996 | 1996BR-0006997 |                |
| BR 9606997A   | January 25, 1996 | 1996WO-EP00294 |                |
| BR 9606997A   |                  | WO 9623487     | Based on       |
| EP 809489A1   | January 25, 1996 | 1996EP-0900973 |                |
| EP 809489A1   | January 25, 1996 | 1996WO-EP00294 |                |
| EP 809489A1   |                  | WO 9623487     | Based on       |
| CZ 9702219A3  | January 25, 1996 | 1996WO-EP00294 |                |
| CZ 9702219A3  | January 25, 1996 | 1997CZ-0002219 |                |
| CZ 9702219A3  |                  | WO 9623487     | Based on       |
| SK 9701015A3  | January 25, 1996 | 1996WO-EP00294 |                |
| SK 9701015A3  | January 25, 1996 | 1997SK-0001015 |                |
| DE 19503338C2 | February 2, 1995 | 1995DE-1003338 |                |
| KR 98701888A  | January 25, 1996 | 1996WO-EP00294 |                |
| KR 98701888A  | August 1, 1997   | 1997KR-0705285 |                |
| KR 98701888A  |                  | WO 9623487     | Based on       |
| AU 707364B    | January 25, 1996 | 1996AU-0044873 |                |
| AU 707364B    |                  | AU 9644873     | Previous Publ. |
| AU 707364B    |                  | WO 9623487     | Based on       |
| NZ 300202A    | January 25, 1996 | 1996NZ-0300202 |                |
| NZ 300202A    | January 25, 1996 | 1996WO-EP00294 |                |

|                |                   |                |                |
|----------------|-------------------|----------------|----------------|
| NZ 300202A     |                   | WO 9623487     | Based on       |
| MX 9705806A1   | July 30, 1997     | 1997MX-0005806 |                |
| US 6074664A    | January 25, 1996  | 1996WO-EP00294 |                |
| US 6074664A    | November 17, 1997 | 1997US-0875723 |                |
| US 6074664A    |                   | WO 9623487     | Based on       |
| JP2000515485W  | January 25, 1996  | 1996JP-0523225 |                |
| JP2000515485W  | January 25, 1996  | 1996WO-EP00294 |                |
| JP2000515485W  |                   | WO 9623487     | Based on       |
| EP 809489B1    | January 25, 1996  | 1996EP-0900973 |                |
| EP 809489B1    | January 25, 1996  | 1996WO-EP00294 |                |
| EP 809489B1    |                   | WO 9623487     | Based on       |
| DE 59606907G   | January 25, 1996  | 1996DE-0506907 |                |
| DE 59606907G   | January 25, 1996  | 1996EP-0900973 |                |
| DE 59606907G   | January 25, 1996  | 1996WO-EP00294 |                |
| DE 59606907G   |                   | EP 809489      | Based on       |
| DE 59606907G   |                   | WO 9623487     | Based on       |
| ES 2159013T3   | January 25, 1996  | 1996EP-0900973 |                |
| ES 2159013T3   |                   | EP 809489      | Based on       |
| CN 1182364A    | January 25, 1996  | 1996CN-0191620 |                |
| HU 200202088A2 | January 25, 1996  | 1996WO-EP00294 |                |
| HU 200202088A2 | January 25, 1996  | 2002HU-0002088 |                |
| HU 200202088A2 |                   | WO 9623487     | Based on       |
| SK 282578B6    | January 25, 1996  | 1996WO-EP00294 |                |
| SK 282578B6    | January 25, 1996  | 1997SK-0001015 |                |
| SK 282578B6    |                   | SK 9701015     | Previous Publ. |
| SK 282578B6    |                   | WO 9623487     | Based on       |
| CZ 290943B6    | January 25, 1996  | 1996WO-EP00294 |                |
| CZ 290943B6    | January 25, 1996  | 1997CZ-0002219 |                |
| CZ 290943B6    |                   | CZ 9702219     | Previous Publ. |
| CZ 290943B6    |                   | WO 9623487     | Based on       |

US 6074664 A INT-CL (IPC): A61C 0/00; A61K 0/00; A61K 9/70; A61K 38/46; A61K 38/48; A61K 47/30; A61L 15/14; A61L 15/38; A61L 15/44; A61M 37/00; A61P 17/02

ABSTRACTED-PUB-NO: EP 809489B

BASIC-ABSTRACT:

A coherent, flat and deformable dosage form for the controlled release of collagen to wounds has the same or smaller size than the wound area and contains defined amts. of homogeneously distributed collagen.

USE - The dosage form is used for the direct application to wounds e.g. of prod. obtd. from Clostridium histolyticum culture filtrate, known as collagenase and contg. a mixt. of collagenases, clostripain and neutral proteases.

It can be conveniently applied to the wound as a number of individual small pieces or in one piece cut to the shape of the wound.

**ADVANTAGE** - In contrast to conventional formulations, e.g. ointments, creams, powders, sprays and plasters, the dosage form enables collagenase to be applied in a precise, uniform and reproducible dose.

**ABSTRACTED-PUB-NO:** US 6074664A

**EQUIVALENT-ABSTRACTS:**

A coherent, flat and deformable dosage form for the controlled release of collagen to wounds has the same or smaller size than the wound area and contains defined amts. of homogeneously distributed collagen.

**USE** - The dosage form is used for the direct application to wounds e.g. of prod. obtd. from Clostridium histolyticum culture filtrate, known as collagenase and contg. a mixt. of collagenases, clostripain and neutral proteases.

It can be conveniently applied to the wound as a number of individual small pieces or in one piece cut to the shape of the wound.

**ADVANTAGE** - In contrast to conventional formulations, e.g. ointments, creams, powders, sprays and plasters, the dosage form enables collagenase to be applied in a precise, uniform and reproducible dose.

A coherent, flat and deformable dosage form for the controlled release of collagen to wounds has the same or smaller size than the wound area and contains defined amts. of homogeneously distributed collagen.

**USE** - The dosage form is used for the direct application to wounds e.g. of prod. obtd. from Clostridium histolyticum culture filtrate, known as collagenase and contg. a mixt. of collagenases, clostripain and neutral proteases.

It can be conveniently applied to the wound as a number of individual small pieces or in one piece cut to the shape of the wound.

**ADVANTAGE** - In contrast to conventional formulations, e.g. ointments, creams, powders, sprays and plasters, the dosage form enables collagenase to be applied in a precise, uniform and reproducible dose.

WO 9623487A

**CHOSEN-DRAWING:** Dwg.0/0

**DERWENT-CLASS:** B04 B07 D16 D22 P32 P34

**CPI-CODES:** B04-C02B1; B04-C03B; B04-C03C; B04-L05C; B04-N02; B12-M10A; B14-N17B; D05-A02C; D09-C04B;

[Previous Doc](#)    [Next Doc](#)    [Go to Doc#](#)

00765751 EMCare No: 30311390

Pain management in patients with multiple sclerosis  
Murray T.J.

Dr. T.J. Murray, Dalhousie MS Research Unit, 5849 University Avenue,  
Halifax, NS B3H 4H7 Canada

AUTHOR EMAIL: jock.murray@dal.ca

Pain Research and Management ( PAIN RES. MANAGE. ) (Canada) 2000, 5/1  
(77-80)

CODEN: PRMAF ISSN: 1203-6765

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH; FRENCH

NUMBER OF REFERENCES: 19

RECORD TYPE: Abstract

Although the idea that pain is not a symptom of multiple sclerosis (MS) continues, many studies have confirmed that over half of MS patients complain of pain. In some patients, it may be in part a result of the exacerbation of the disease. In other patients, it is an acute pain problem such as trigeminal neuralgia, bladder spasms, acute dysesthesia, Lhermitte's phenomenon or painful tonic spasms. In even more cases, it is chronic pain that can take the form of dysesthesia, or repeated muscle spasms and aching. Although MS can cause pain, increasing disability can also produce other complications that are painful such as pressure palsies, decubiti, the effects of poorly fitting wheelchairs, or the musculoskeletal pain that results from the effort to maintain head position and posture with weakened muscles. All of the problem that MS patients experience do not necessarily result from their MS. MS patients can develop all of the medical conditions and pain situations that afflict the rest of the population, and these are usually manageable when the correct diagnosis is made and the approach is focused. Overall, most of the conditions causing pain in MS can be prevented, eliminated or improved, and the remaining patients with chronic pain are managed with strategies that are useful in approaching chronic pain in other situations.

Copyright 2006 Elsevier B.V., All rights reserved.

BRAND NAME/MANUFACTURER NAME: rebif/Serono/United States

MANUFACTURER NAMES: Serono/United States

DESCRIPTORS:

\*pain; \*multiple sclerosis; \*hospital patient; \*trigeminus neuralgia; \* demyelination  
methylprednisolone; gabapentin; lamotrigine; mexiletine; morphine; nortriptyline; tizanidine; baclofen; amantadine; desipramine; amitriptyline; betala interferon; ~~botulinum toxin~~; carbamazepine; patient; chronic pain; muscle spasm; ~~dysesthesia~~; dose response; face pain; fatigue; Lhermitte Duclos disease; human; optic nerve disease; nerve stimulation; physiotherapy; tonic seizure; bladder spasm; disability; paralysis; wheelchair; head position; body posture; muscle; population; diagnosis; disease exacerbation

11565805 EMBASE No: 2002137180

Medical issues that impact life care planning for spinal cord injury  
Winkler T.

Dr. T. Winkler, Ozark Area Rehabilitation Services, Springfield, MO  
United States

Topics in Spinal Cord Injury Rehabilitation ( TOP. SPINAL CORD INJ.  
REHABIL. ) (United States) 2002, 7/4 (21-27)

CODEN: TSIRF ISSN: 1082-0744

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 10

BRAND NAME/MANUFACTURER NAME: fosamax; indocin; didronel; valium; zanaflex;  
florinef; proamatine; procardia; lovenox; oxandrin

DRUG DESCRIPTORS:

calcium--drug therapy--dt; calcium--oral drug administration--po; vitamin D  
--drug therapy--dt; vitamin D--oral drug administration--po; alendronic  
acid--drug therapy--dt; nonsteroid antiinflammatory agent--drug therapy--dt  
; indometacin--drug therapy--dt; etidronic acid--drug therapy--dt;  
etidronic acid--pharmacology--pd; diazepam--drug therapy--dt; tizanidine  
--drug therapy--dt; botulinum toxin A--drug therapy--dt; fludrocortisone  
--drug therapy--dt; sodium chloride--drug therapy--dt; midodrine--drug  
therapy--dt; midodrine--pharmacology--pd; phenoxybenzamine--drug therapy  
--dt; nifedipine--drug therapy--dt; nifedipine--pharmacology--pd;  
enoxaparin--drug therapy--dt; anticoagulant agent--drug therapy--dt;  
laxative--drug therapy--dt; oxandrolone--drug therapy--dt; oxandrolone  
--pharmacology--pd

MEDICAL DESCRIPTORS:

\*spinal cord injury--rehabilitation--rh; \*treatment planning  
health program; patient counseling; patient education; musculoskeletal  
system; bone mineralization; osteoporosis--drug therapy--dt; osteoporosis  
--therapy--th; hormone substitution; weight bearing; heterotopic  
ossification--complication--co; heterotopic ossification--drug therapy--dt;  
heterotopic ossification--etiology--et; heterotopic ossification--therapy  
--th; treatment indication; repetitive strain injury--complication--co;  
repetitive strain injury--surgery--su; spasticity--drug therapy--dt;  
spasticity--etiology--et; decubitus--complication--co;  
decubitus--disease management--dm; decubitus--etiology--et;  
health care cost; cardiovascular risk; blood pressure regulation; heart  
arrhythmia--complication--co; hypotension--complication--co; hypotension  
--drug therapy--dt; autonomic dysreflexia--complication--co; autonomic  
dysreflexia--drug therapy--dt; autonomic dysreflexia--etiology--et; deep  
vein thrombosis--complication--co; deep vein thrombosis--drug therapy--dt;  
deep vein thrombosis--etiology--et; gastrointestinal disease--complication  
--co; gastrointestinal disease--drug therapy--dt; gastrointestinal disease  
--etiology--et; gastrointestinal disease--therapy--th; kidney disease  
--complication--co; metabolic disorder--complication--co; metabolic  
disorder--drug therapy--dt; metabolic disorder--etiology--et; human; review

DRUG TERMS (UNCONTROLLED): oxandrin

CAS REGISTRY NO.: 7440-70-2 (calcium); 66376-36-1 (alendronic acid);  
53-86-1, 74252-25-8, 7681-54-1 (indometacin); 2809-21-4, 3794-83-0,  
58449-82-4, 7414-83-7 (etidronic acid); 439-14-5 (diazepam); 51322-75-9  
, 64461-82-1 (tizanidine); 93384-43-1 (botulinum toxin A); 127-31-1 (br)  
fludrocortisone); 7647-14-5 (sodium chloride); 3092-17-9, 42794-76-3 (br)  
midodrine); 59-96-1, 63-92-3 (phenoxybenzamine); 21829-25-4 (nifedipine  
); 9041-08-1 (enoxaparin); 53-39-4 (oxandrolone)

SECTION HEADINGS:

- 005 General Pathology and Pathological Anatomy
- 017 Public Health, Social Medical and Epidemiology
- 033 Orthopedic Surgery
- 036 Health Policy, Economics and Management
- 037 Drug Literature Index

Ill  
Neg  
10/13/03